These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 1697370)

  • 1. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W; Martorana PA; Schölkens BA
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].
    Schölkens BA; Linz W
    Klin Wochenschr; 1991; 69 Suppl 24():1-5. PubMed ID: 1865630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.
    Linz W; Schölkens BA; Kaiser J; Just M; Qi BY; Albus U; Petry P
    Cardiovasc Drugs Ther; 1989 Dec; 3(6):873-82. PubMed ID: 2535056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local inhibition of angiotensin II formation and bradykinin degradation in isolated hearts.
    Schölkens BA; Linz W
    Clin Exp Hypertens A; 1988; 10(6):1259-70. PubMed ID: 2975971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S75-82. PubMed ID: 2485067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
    Schölkens BA; Linz W
    Clin Physiol Biochem; 1990; 8 Suppl 1():33-43. PubMed ID: 2147878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():53-6. PubMed ID: 7856280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist.
    Schölkens BA; Linz W; König W
    J Hypertens Suppl; 1988 Dec; 6(4):S25-8. PubMed ID: 2853732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bradykinin-mediated metabolic effects in isolated perfused rat hearts.
    Schoelkens BA; Linz W
    Agents Actions Suppl; 1992; 38 ( Pt 2)():36-42. PubMed ID: 1462841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the thromboxane synthetase inhibitor HOE 944, prostacyclin and indomethacin on reperfusion arrhythmias, cardiodynamics and metabolism in isolated ischemic rat hearts.
    Linz W; Lau HH; Beck G; Schökens BA
    Biomed Biochim Acta; 1988; 47(10-11):S23-6. PubMed ID: 3073762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.
    Martorana PA; Schölkens BA
    Agents Actions Suppl; 1992; 38 ( Pt 3)():98-102. PubMed ID: 1462888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
    Schriefer JA; Broudy EP; Hassen AH
    J Pharmacol Exp Ther; 2001 Sep; 298(3):970-5. PubMed ID: 11504792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction.
    Schölkens BA; Linz W; Martorana PA
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S26-30. PubMed ID: 1725038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
    Linz W; Wiemer G; Schölkens BA
    Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts.
    Linz W; Schölkens BA; Han YF
    J Cardiovasc Pharmacol; 1986; 8 Suppl 10():S91-9. PubMed ID: 2438498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts.
    Hatta E; Maruyama R; Marshall SJ; Imamura M; Levi R
    J Pharmacol Exp Ther; 1999 Mar; 288(3):919-27. PubMed ID: 10027827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.
    Rastegar MA; Marchini F; Morazzoni G; Vegh A; Papp JG; Parratt JR
    Br J Pharmacol; 2000 Feb; 129(4):671-80. PubMed ID: 10683191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.